Home > Keywords > Thématique > Science

Science

Articles

  • 3rd Annual RNAi-Based Therapeutics Summit from April 19th to 21th, 2022, in Boston
    12 April 2022, by Elodie DORMES

    Michel KHRESTCHATISKY, Scientific Counsel, will have a talk entitled “Development of Molecular Vectors for Targeted Delivery of RNAi” and Elodie DORMES, Sr BD Manager, will also be there and pleased to meet you in person during the summit.

  • Two research groups specialized in CNS drug delivery and in the development of therapeutic strategies for glioblastoma give in vivo POC on one of the peptide vectors described by Vect-Horus
    28 January 2019, by Jonathan NOWAK

    Two groups of the Institute of Hematology, Huazhong University in Wuhan and the Key Laboratory of Smart Drug Delivery, Fudan University in Shanghai, well known and specialized in CNS drug delivery and in the development of therapeutic strategies for glioblastoma, show evidence in mice (Zhang et al., 2013, Biomaterials) of nanoparticle targeting to the brain and glioblastoma with therapeutic benefit, with one of the peptide vectors described by VECT-HORUS in Malcor et al. (2012, J Med Chem).

  • Vect-Horus focuses on Target engagement and intracellular delivery of LDLR conjugates to design new targeted drug therapies
    27 November 2019, by Elodie DORMES

    Varini et al. J Control Release 2019
    Targeted delivery to specific tissues and subcellular compartments is of paramount importance to optimize therapeutic or diagnostic interventions while minimizing side-effects. Using recently identified LDL receptor (LDLR) -targeting small synthetic peptide-vectors conjugated to model cargos of different nature and size, we investigated in LDLR-expressing cells the impact of vector-cargo molecular engineering and coupling valency, as well as the (…)

  • How blood–brain barrier technology is unleashing CNS therapies
    18 March 2025, by Emmanuelle BETTENDORF

    We are proud to be featured in Nature, in an article exploring how we are enabling targeted drug delivery across the blood–brain barrier.
    This article highlights the potential of our VECTrans platform, which has the potential to transform the treatment of neurodegenerative disorders. The article goes into the science and data behind our approach as well as our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, Inc.
    Click below for the full article.
    👉 (…)

  • NTSR2 is induced in astrocytes and brain endothelial cells in relation to neuroinflammation following pilocarpine-induced seizures in rats
    30 September 2021, by Elodie DORMES

    Neurotensin (NT) acts as a primary neurotransmitter and neuromodulator in the CNS and has been involved in a number of CNS pathologies including epilepsy. NT mediates its central and peripheral effects by interacting with the NTSR1, NTSR2, and Sort1/NTSR3 receptor subtypes. To date, little is known about the precise expression of the NT receptors in brain neural cells and their regulation in pathology. In the present work, we studied the cellular distribution of the NTSR2 protein in the rat (…)